Tag: aspirin

1. Clopidogrel monotherapy reduced long-term rates of all-cause mortality, non-fatal myocardial infarction, and stroke after drug-eluting stent placement compared with aspirin monotherapy. 2. The superiority of clopidogrel was seen for both thrombotic and bleeding endpoints and was consistent across demographic groups. Evidence Rating Level: 1 (Excellent)  Study Rundown: Patients who receive percutaneous...

1. Preventative aspirin was used uniformly by persons with diabetes across age groups, while in persons without diabetes it was used less in young seniors (60-69 and 70-79) and equally in those 80+, potentially outside of clinical recommendations. 2. Based on the results of this study and current guidelines, a...

1. Guided selection of antiplatelet therapy reduced rates of major adverse cardiovascular event rates compared to standard therapy. 2. Guided selection strategy was beneficial for both escalation and de-escalation of standard therapy, balancing patient-dependent ischemic and bleeding risks.  Evidence Rating Level: 1 (Excellent) Study Rundown: Patients who undergo percutaneous coronary intervention (PCI)...

1. In patients treated with direct oral anticoagulants (DOACs) for atrial fibrillation or venous thromboembolism (VTE), adding aspirin (ASA) was associated with increased bleeding events. 2. Adding ASA to DOAC treatment for patients with atrial fibrillation or VTE did not improve the incidence of thrombotic events. Evidence Rating Level: 2 (Good) Study Rundown: Aspirin...

1. Polypill plus aspirin treatment was shown to decrease the incidence of cardiovascular events compared to placebo in patients without cardiovascular disease. 2. Adverse events such as hypotension and dizziness were shown to be higher in the polypill-only group compared to the placebo group. Evidence Rating Level: 1 (Excellent) Study Rundown: Polypills combining...

1. In patients treated with direct oral anticoagulants (DOACs) for atrial fibrillation or venous thromboembolism (VTE), adding aspirin (ASA) was associated with increased bleeding events. 2. Adding ASA to DOAC treatment for patients with atrial fibrillation or VTE did not improve the incidence of thrombotic events. Evidence Rating Level: 2 (Good) Study...

1. Polypill plus aspirin treatment was shown to decrease the incidence of cardiovascular events compared to placebo in patients without cardiovascular disease. 2. Adverse events such as hypotension and dizziness were shown to be higher in the polypill-only group compared to the placebo group. Evidence Rating Level: 1 (Excellent) Study Rundown: Polypills...

1. Adding celecoxib to adjuvant chemotherapy did not increase disease-free survival or overall survival compared to placebo in patients with stage III colon cancer. 2. Celecoxib treatment led to increased incidence of hypertension and elevated levels of creatinine versus placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Aspirin and cyclooxygenase 2 (COX-2)...

1. Patients status-post placement of drug-eluting stents (DES) for acute coronary syndrome received three months of Ticagrelor and Aspirin dual-antiplatelet therapy (DAPT), followed by nine months of DAPT or Ticagrelor monotherapy. 2. At one year, patients who received Ticagrelor alone experienced significantly fewer adverse major bleeding events. There was no...